6 results on '"Pappas, D.A."'
Search Results
2. Brief Report: The Role of Rare Protein-Coding Variants in Anti-Tumor Necrosis Factor Treatment Response in Rheumatoid Arthritis
- Author
-
Cui, J., Diogo, D., Stahl, E.A., Canhao, H., Mariette, X., Greenberg, J.D., Okada, Y., Pappas, D.A., Fulton, R.S., Tak, P.P., Nurmohamed, M.T., Lee, A., Larson, D.E., Kurreeman, F., Deluca, T.L., O'Laughlin, M., Fronick, C.C., Fulton, L.L., Mardis, E.R., Horst-Bruinsma, I.E., Wolbink, G.J., Gregersen, P.K., Kremer, J.M, Crusius, J.B.A., Vries, N. de, Huizinga, T.W.J., Fonseca, J.E., Miceli-Richard, C., Karlson, E.W., Coenen, M.J.H., Barton, A., Plenge, R.M., Raychaudhuri, S., Cui, J., Diogo, D., Stahl, E.A., Canhao, H., Mariette, X., Greenberg, J.D., Okada, Y., Pappas, D.A., Fulton, R.S., Tak, P.P., Nurmohamed, M.T., Lee, A., Larson, D.E., Kurreeman, F., Deluca, T.L., O'Laughlin, M., Fronick, C.C., Fulton, L.L., Mardis, E.R., Horst-Bruinsma, I.E., Wolbink, G.J., Gregersen, P.K., Kremer, J.M, Crusius, J.B.A., Vries, N. de, Huizinga, T.W.J., Fonseca, J.E., Miceli-Richard, C., Karlson, E.W., Coenen, M.J.H., Barton, A., Plenge, R.M., and Raychaudhuri, S.
- Abstract
Item does not contain fulltext, OBJECTIVE: In many rheumatoid arthritis (RA) patients, disease is controlled with anti-tumor necrosis factor (anti-TNF) biologic therapies. However, in a significant number of patients, the disease fails to respond to anti-TNF therapy. We undertook the present study to examine the hypothesis that rare and low-frequency genetic variants might influence response to anti-TNF treatment. METHODS: We sequenced the coding region of 750 genes in 1,094 RA patients of European ancestry who were treated with anti-TNF. After quality control, 690 genes were included in the analysis. We applied single-variant association and gene-based association tests to identify variants associated with anti-TNF treatment response. In addition, given the key mechanistic role of TNF, we performed gene set analyses of 27 TNF pathway genes. RESULTS: We identified 14,420 functional variants, of which 6,934 were predicted as nonsynonymous 2,136 of which were further predicted to be "damaging." Despite the fact that the study was well powered, no single variant or gene showed study-wide significant association with change in the outcome measures disease activity or European League Against Rheumatism response. Intriguingly, we observed 3 genes, of 27 with nominal signals of association (P < 0.05), that were involved in the TNF signaling pathway. However, when we performed a rigorous gene set enrichment analysis based on association P value ranking, we observed no evidence of enrichment of association at genes involved in the TNF pathway (Penrichment = 0.15, based on phenotype permutations). CONCLUSION: Our findings suggest that rare and low-frequency protein-coding variants in TNF signaling pathway genes or other genes do not contribute substantially to anti-TNF treatment response in patients with RA.
- Published
- 2017
3. TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits
- Author
-
Diogo, D., Bastarache, L., Liao, K.P., Graham, R.R., Fulton, R.S., Greenberg, J.D., Eyre, S., Bowes, J., Cui, J., Lee, A., Pappas, D.A., Kremer, H., Barton, A., Coenen, M.J.H., Franke, B., Kiemeney, L.A.L.M., Mariette, X., Richard-Miceli, C., Canhao, H., Fonseca, J.E., Vries, N. de, Tak, P.P., Crusius, J.B.A., Nurmohamed, M.T., Kurreeman, F., Mikuls, T.R., Okada, Y., Stahl, E.A., Larson, D.E., Deluca, T.L., O'Laughlin, M., Fronick, C.C., Fulton, L.L., Kosoy, R., Ransom, M., Bhangale, T.R., Ortmann, W., Cagan, A., Gainer, V., Karlson, E.W., Kohane, I., Murphy, S.N., Martin, J., Zhernakova, A., Klareskog, L., Padyukov, L., Worthington, J., Mardis, E.R., Seldin, M.F., Gregersen, P.K., Behrens, T., Raychaudhuri, S., Denny, J.C., Plenge, R.M., Diogo, D., Bastarache, L., Liao, K.P., Graham, R.R., Fulton, R.S., Greenberg, J.D., Eyre, S., Bowes, J., Cui, J., Lee, A., Pappas, D.A., Kremer, H., Barton, A., Coenen, M.J.H., Franke, B., Kiemeney, L.A.L.M., Mariette, X., Richard-Miceli, C., Canhao, H., Fonseca, J.E., Vries, N. de, Tak, P.P., Crusius, J.B.A., Nurmohamed, M.T., Kurreeman, F., Mikuls, T.R., Okada, Y., Stahl, E.A., Larson, D.E., Deluca, T.L., O'Laughlin, M., Fronick, C.C., Fulton, L.L., Kosoy, R., Ransom, M., Bhangale, T.R., Ortmann, W., Cagan, A., Gainer, V., Karlson, E.W., Kohane, I., Murphy, S.N., Martin, J., Zhernakova, A., Klareskog, L., Padyukov, L., Worthington, J., Mardis, E.R., Seldin, M.F., Gregersen, P.K., Behrens, T., Raychaudhuri, S., Denny, J.C., and Plenge, R.M.
- Abstract
Contains fulltext : 154077.pdf (publisher's version ) (Open Access), Despite the success of genome-wide association studies (GWAS) in detecting a large number of loci for complex phenotypes such as rheumatoid arthritis (RA) susceptibility, the lack of information on the causal genes leaves important challenges to interpret GWAS results in the context of the disease biology. Here, we genetically fine-map the RA risk locus at 19p13 to define causal variants, and explore the pleiotropic effects of these same variants in other complex traits. First, we combined Immunochip dense genotyping (n = 23,092 case/control samples), Exomechip genotyping (n = 18,409 case/control samples) and targeted exon-sequencing (n = 2,236 case/controls samples) to demonstrate that three protein-coding variants in TYK2 (tyrosine kinase 2) independently protect against RA: P1104A (rs34536443, OR = 0.66, P = 2.3 x 10(-21)), A928V (rs35018800, OR = 0.53, P = 1.2 x 10(-9)), and I684S (rs12720356, OR = 0.86, P = 4.6 x 10(-7)). Second, we show that the same three TYK2 variants protect against systemic lupus erythematosus (SLE, Pomnibus = 6 x 10(-18)), and provide suggestive evidence that two of the TYK2 variants (P1104A and A928V) may also protect against inflammatory bowel disease (IBD; P(omnibus) = 0.005). Finally, in a phenome-wide association study (PheWAS) assessing >500 phenotypes using electronic medical records (EMR) in >29,000 subjects, we found no convincing evidence for association of P1104A and A928V with complex phenotypes other than autoimmune diseases such as RA, SLE and IBD. Together, our results demonstrate the role of TYK2 in the pathogenesis of RA, SLE and IBD, and provide supporting evidence for TYK2 as a promising drug target for the treatment of autoimmune diseases.
- Published
- 2015
4. Genetics of rheumatoid arthritis contributes to biology and drug discovery
- Author
-
Okada, Y., Wu, D., Trynka, G., Raj, T., Terao, C., Ikari, K., Kochi, Y., Ohmura, K., Suzuki, A., Yoshida, S., Graham, R.R., Manoharan, A., Ortmann, W., Bhangale, T., Denny, J.C., Carroll, R.J., Eyler, A.E., Greenberg, J.D., Kremer, J.M, Pappas, D.A., Jiang, L., Yin, J., Ye, L, Su, D.F., Yang, J., Xie, G., Keystone, E., Westra, H.J., Esko, T., Metspalu, A., Zhou, X., Gupta, N., Mirel, D., Stahl, E.A., Diogo, D., Cui, J., Liao, K., Guo, M.H., Myouzen, K., Kawaguchi, T., Coenen, M.J.H., Riel, P.L.C.M. van, Laar, M.A. van der, Guchelaar (LUMC), H.J., Huizinga, T.W.J., Dieude, P., Mariette, X., Bridges, S.L., Jr., Zhernakova, A., Toes, R.E., Tak, P.P., Miceli-Richard, C., Bang, S.Y., Lee, H.S., Martin, J., Gonzalez-Gay, M.A., Rodriguez-Rodriguez, L., Rantapaa-Dahlqvist, S., Arlestig, L., Choi, H.K., Kamatani, Y., Galan, P., Lathrop, M., Eyre, S., Bowes, J., Barton, A., Vries, N. de, Moreland, L.W., Criswell, L.A., Karlson, E.W., Taniguchi, A., Yamada, R., Kubo, M., Liu, J.S., Bae, S.C., Worthington, J., Padyukov, L., Klareskog, L., Gregersen, P.K., Raychaudhuri, S., Stranger, B.E., Jager, P.L. De, Franke, L., Visscher, P.M., Brown, M.A., Yamanaka, H., Mimori, T., Takahashi, A., Xu, H., Behrens, T.W., Siminovitch, K.A., Momohara, S., Matsuda, F., Yamamoto, K., Plenge, R.M., et al., Okada, Y., Wu, D., Trynka, G., Raj, T., Terao, C., Ikari, K., Kochi, Y., Ohmura, K., Suzuki, A., Yoshida, S., Graham, R.R., Manoharan, A., Ortmann, W., Bhangale, T., Denny, J.C., Carroll, R.J., Eyler, A.E., Greenberg, J.D., Kremer, J.M, Pappas, D.A., Jiang, L., Yin, J., Ye, L, Su, D.F., Yang, J., Xie, G., Keystone, E., Westra, H.J., Esko, T., Metspalu, A., Zhou, X., Gupta, N., Mirel, D., Stahl, E.A., Diogo, D., Cui, J., Liao, K., Guo, M.H., Myouzen, K., Kawaguchi, T., Coenen, M.J.H., Riel, P.L.C.M. van, Laar, M.A. van der, Guchelaar (LUMC), H.J., Huizinga, T.W.J., Dieude, P., Mariette, X., Bridges, S.L., Jr., Zhernakova, A., Toes, R.E., Tak, P.P., Miceli-Richard, C., Bang, S.Y., Lee, H.S., Martin, J., Gonzalez-Gay, M.A., Rodriguez-Rodriguez, L., Rantapaa-Dahlqvist, S., Arlestig, L., Choi, H.K., Kamatani, Y., Galan, P., Lathrop, M., Eyre, S., Bowes, J., Barton, A., Vries, N. de, Moreland, L.W., Criswell, L.A., Karlson, E.W., Taniguchi, A., Yamada, R., Kubo, M., Liu, J.S., Bae, S.C., Worthington, J., Padyukov, L., Klareskog, L., Gregersen, P.K., Raychaudhuri, S., Stranger, B.E., Jager, P.L. De, Franke, L., Visscher, P.M., Brown, M.A., Yamanaka, H., Mimori, T., Takahashi, A., Xu, H., Behrens, T.W., Siminovitch, K.A., Momohara, S., Matsuda, F., Yamamoto, K., Plenge, R.M., and et al.
- Abstract
Item does not contain fulltext, A major challenge in human genetics is to devise a systematic strategy to integrate disease-associated variants with diverse genomic and biological data sets to provide insight into disease pathogenesis and guide drug discovery for complex traits such as rheumatoid arthritis (RA). Here we performed a genome-wide association study meta-analysis in a total of >100,000 subjects of European and Asian ancestries (29,880 RA cases and 73,758 controls), by evaluating approximately 10 million single-nucleotide polymorphisms. We discovered 42 novel RA risk loci at a genome-wide level of significance, bringing the total to 101 (refs 2 - 4). We devised an in silico pipeline using established bioinformatics methods based on functional annotation, cis-acting expression quantitative trait loci and pathway analyses--as well as novel methods based on genetic overlap with human primary immunodeficiency, haematological cancer somatic mutations and knockout mouse phenotypes--to identify 98 biological candidate genes at these 101 risk loci. We demonstrate that these genes are the targets of approved therapies for RA, and further suggest that drugs approved for other indications may be repurposed for the treatment of RA. Together, this comprehensive genetic study sheds light on fundamental genes, pathways and cell types that contribute to RA pathogenesis, and provides empirical evidence that the genetics of RA can provide important information for drug discovery.
- Published
- 2014
5. Therapy With Certolizumab Pegol And Other Tnf-A Inhibitors In Elderly Patients With Rheumatoid Arthritis: Results From The Corrona Registry
- Author
-
Pappas, D.A, primary, Etzel, C.J., additional, Bedenbaugh, A., additional, Tambiah, J., additional, and Greenberg, J.D., additional
- Published
- 2014
- Full Text
- View/download PDF
6. PMS11 - Therapy With Certolizumab Pegol And Other Tnf-A Inhibitors In Elderly Patients With Rheumatoid Arthritis: Results From The Corrona Registry
- Author
-
Pappas, D.A, Etzel, C.J., Bedenbaugh, A., Tambiah, J., and Greenberg, J.D.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.